Secondary exposure to testosterone from patients receiving replacement therapy with transdermal testosterone gels

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

The AndroGel testosterone gel transfer studies discussed in this editorial and the medical writing support for preparation of this editorial were funded by Abbott.

Declaration of financial/other relationships

T.L.Z. and M.G.M. are employed by Abbott and own Abbott stock. A.D.R. has been on a scientific advisory board for Global Stevia Institute, has consulted for Abbott, Ipsen/Tercica, Insmed, and NovoNordisk, has received payment for the development of educational presentations from Scherer and UpToDate, and has stock or stock options in Insmed.

Acknowledgments

Medical writing support for preparation of this editorial was provided by Robin Smith, PhD, of The Curry Rockefeller Group, LLC, Tarrytown, NY, USA. Funding for this support was provided by Abbott.